ELI LILLY & Co - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 4, 2026, reports the financial results for Eli Lilly and Company for the quarter and full year ended December 31, 2025. The filing incorporates by reference a press release (Exhibit 99.1) detailing these results.
Key Financial Metrics
The provided text serves as a cover sheet and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached Exhibit 99.1 press release, which is not included in the input text.
Material Changes
No specific material changes versus prior periods are detailed in this filing text. The document solely references the existence of the results announcement.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, risk factors, or details on contingencies. It notes that the information in Item 2.02 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, earnings, and cash flow figures for Q4 and FY 2025.
- Verify the specific details of the 1.625% Notes due 2026 listed as registered securities, given the filing date is February 2026.
- Confirm any updated guidance or strategic shifts mentioned in the full press release text.
- Check for any unusual items or one-time charges disclosed in the full financial results.